COMMUNIQUÉS West-GlobeNewswire

BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
18/09/2026
POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and [...]
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
18/09/2026
Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non- [...]
Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)
18/09/2026
If approved, Sogroya® (somapacitan) would be the first and only growth hormone treatment approved for idiopathic short stature in the EU, providing a much-needed treatment option for children and their families affected [...]
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
18/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a [...]
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
18/09/2026
Press release – No. 16 / 2026 Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome The CHMP of the European Medicines Agency has recommended the approval [...]
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0650 Per Share
18/09/2026
SAN JUAN CAPISTRANO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Ipsen appoints Mariette Finet to its Board of Directors
18/09/2026
Ipsen appoints Mariette Finet to its Board of Directors PARIS, FRANCE, 18 SEPTEMBER 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Mariette Finet as a Director to its Board of Directors, [...]
Ipsen nomme Mariette Finet administratrice au sein de son Conseil d’administration
18/09/2026
Ipsen nomme Mariette Finet administratrice au sein de son Conseil d’administration PARIS, FRANCE, 18 SEPTEMBRE 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui la cooptation de Mariette Finet en qualité d’ [...]
DXS INTERNATIONAL PLC (AQSE: DXSP): Timing of FY Results to 30 April 2026
18/09/2026
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union ( [...]
Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering
18/09/2026
SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, [...]
Immumax Expands Global Access to the E-Tapper to Empower Natural Health Management from Home
18/09/2026
HONG KONG, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Immumax, a pioneer in alternative health and wellness solutions, has announced the international expansion of its online training and consultation services. Focused on [...]
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
18/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of [...]
BioTech Social Announces Advisory Board to Advance Financial Innovation for Life Science Companies
18/09/2026
BETHESDA, MD, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Experienced leaders across biotechnology, finance, technology, patient engagement, communications, and company building will advise BSI as it builds financial [...]
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
17/09/2026
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
17/09/2026
IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a [...]
Vireo Growth Inc. Announces Issuance of Shares in Connection with Altmore Settlement
17/09/2026
MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform today announced that, in connection [...]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/09/2026
WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
17/09/2026
September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of [...]
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
17/09/2026
New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in [...]

Pages